{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "Germany Reviews a New Pharma “Location Clause” (Standortklausel) for Pricing & Reimbursement Incentives – Improvement or Worsening for the Pharmaceutical Industry?",
    "url": "https://www.lexblog.com/2026/10/07/germany-reviews-a-new-pharma-location-clause-standortklausel-for-pricing-reimbursement-incentives-improvement-or-worsening-for-the-pharmaceutical-industry/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-NWQNCACF",
        "url": "https://www.lexblog.com/lib/NWQNCACF/"
    },
    "datePublished": "2026-10-07T22:44:05-04:00",
    "dateModified": "2026-10-07T22:44:18-04:00",
    "author": {
        "@type": "Person",
        "name": "Dr. Dr. Adem Koyuncu, Maximilian Aretz"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Covington & Burling LLP"
    },
    "organizationScope": "at-publication",
    "isPartOf": "Global Policy Watch",
    "about": "Administrative and Regulatory · Health Care and Life Sciences",
    "sourceUrl": "https://www.globalpolicywatch.com/?p=16833",
    "sourceStability": "may-move"
}